Related Experiment Video

Updated: Jun 4, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Emerging options in the treatment of dyslipidemias: a bright future?

Matilda Florentin1, Evangelos N Liberopoulos, Dimitri P Mikhailidis

  • 1University of Ioannina, School of Medicine, Department of Internal Medicine, Ioannina 45110, Greece.

Expert Opinion on Emerging Drugs
|February 18, 2011
PubMed

Insights

New lipid-modifying drugs show promise in reducing cardiovascular disease (CVD) risk for patients with hypercholesterolemia who don't reach low-density lipoprotein cholesterol (LDL-C) targets with statins.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Hypercholesterolemia is a significant risk factor for cardiovascular disease (CVD).
  • Low-density lipoprotein cholesterol (LDL-C) reduction is crucial for decreasing CVD morbidity and mortality.
  • Many patients fail to achieve target LDL-C levels with existing therapies like statins, indicating a residual CVD risk.

Purpose of the Study:

  • To review the efficacy and safety of emerging lipid-modifying agents.
  • To explore novel therapeutic strategies for managing hypercholesterolemia and residual CVD risk.

Main Methods:

  • Review of emerging drugs targeting high-density lipoprotein cholesterol (HDL-C) elevation.
  • Examination of apolipoprotein (apo) A-I therapies, apo A-I mimetic peptides, and reconstituted HDL.
  • Inclusion of cholesterol ester transfer protein inhibitors, microsomal triglyceride transfer protein inhibitors, and antisense oligonucleotides.

Main Results:

  • Emerging agents demonstrate potential for potent reduction of residual CVD risk.
  • Various novel drug classes are under investigation for their lipid-modifying capabilities.

Conclusions:

  • Several investigational lipid-modifying agents hold promise for reducing residual CVD risk.
  • Further clinical outcome studies are necessary to confirm the efficacy of these agents in practice.
Abstract

More Related Videos

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...